Daily Endocrinology Research Analysis
Analyzed 58 papers and selected 3 impactful papers.
Summary
Today’s top endocrinology research advances span therapeutics, risk stratification, and causal inference. A multicenter RCT shows that non-invasive tests can feasibly monitor semaglutide response in MASH, while a large NHANES cohort identifies NT-proBNP and hs-cTnT as leading predictors of mortality in dysglycemia. Mendelian randomization suggests GLP-1 receptor agonism may reduce endometrioid ovarian cancer risk via metabolic mediators.
Research Themes
- Non-invasive endpoints for metabolic liver disease trials
- Cardiorenal biomarkers for mortality risk stratification in dysglycemia
- Causal effects of GLP-1R agonism on cancer risk via metabolic mediators
Selected Articles
1. Clinical Trial: Semaglutide Versus Placebo in NIT-Assessed MASH-A Multicenter Randomised Placebo-Controlled Trial (SAMARA).
In a 52-week multicenter, double-blind RCT (n=55), semaglutide’s effects in at-risk MASH were successfully monitored using non-invasive tests (FAST, ALT/AST, MRI-PDFF). The trial demonstrates the feasibility and effectiveness of an NIT-based strategy for both enrollment and response assessment.
Impact: Provides randomized evidence that NITs can operationalize semaglutide assessment in MASH, bridging trial design and real-world monitoring. Supports guideline movement toward non-invasive endpoints.
Clinical Implications: Clinicians can consider NITs such as FAST and MRI-PDFF to monitor semaglutide response in at-risk MASH, reducing reliance on liver biopsy and enabling scalable follow-up.
Key Findings
- A 52-week multicenter double-blind RCT enrolled 55 at-risk MASH patients to semaglutide vs placebo.
- NITs (FAST, ALT, AST, MRI-PDFF) effectively captured treatment response over time.
- An NIT-based approach was feasible for both eligibility determination and longitudinal monitoring.
Methodological Strengths
- Randomized, double-blind, placebo-controlled multicenter design over 52 weeks
- Use of validated non-invasive endpoints (FAST, MRI-PDFF) aligned with contemporary practice
Limitations
- Small sample size (n=55) limits precision and subgroup analyses
- Abstract does not report absolute effect sizes by arm, constraining interpretation of magnitude
Future Directions: Larger RCTs should validate NIT thresholds for response and link NIT changes to histologic and hard clinical outcomes.
BACKGROUND/AIMS: Non-invasive test (NIT)-based assessment of eligibility and treatment response with semaglutide is needed to inform clinical practice guidance. Therefore, utilising a randomised, placebo-controlled study design, we evaluated the utility of NITs to assess eligibility and treatment response in patients with suspected at-risk MASH randomised to semaglutide versus placebo. METHODS: In this multicentre, randomised, double-blind placebo-controlled 52-week trial, patients meeting AASLD criteria for MASLD with BMI ≥ 27 kg/m RESULTS: Fifty-five participants were randomised (55% women, 20% with diabetes). Mean (SD) age, BMI, and FAST at baseline were 48.8 (14) years, 40.2 (15) kg/m CONCLUSIONS: A NIT-based approach to identify at-risk MASH patients for semaglutide treatment is feasible and effective. This study provides RCT data showing that FAST, ALT, AST and MRI-PDFF can be used to monitor treatment response.
2. Mendelian randomization study of GLP-1R effects on ovarian cancer subtypes mediated by metabolic factors.
Genetic instruments for GLP-1R across endocrine tissues indicate that higher pancreatic GLP-1R activity is associated with reduced endometrioid ovarian cancer risk, with mediation by body composition and lipid metabolites. Subtype specificity was observed, with null findings for other ovarian cancer subtypes.
Impact: Uses multi-omic MR to provide causal evidence linking GLP-1R agonism to lower risk of a specific ovarian cancer subtype, informing oncology-endocrine intersections and potential prevention trials.
Clinical Implications: While not practice-changing yet, findings support prioritizing ENOC-focused clinical trials of GLP-1R agonists and motivate monitoring of metabolic mediators as biomarkers.
Key Findings
- Pancreatic GLP-1R gene expression associated with lower risk of overall ovarian cancer (OR 0.94, 95% CI 0.89–1.00) and endometrioid ovarian cancer (OR 0.83, 95% CI 0.72–0.95).
- Validation using GLP-1R splicing instruments in pancreas showed strong association for ENOC (OR 0.13, 95% CI 0.02–0.86).
- Phenome-wide and mediation MR implicated body composition and metabolic factors (e.g., 18:2 linoleic acid) as mediators.
Methodological Strengths
- Use of multi-layer genetic instruments (expression, protein, splicing, methylation) across endocrine tissues
- Large-scale GWAS meta-analysis (29,066 cases; 461,542 controls) with mediation analyses
Limitations
- MR assumptions (no horizontal pleiotropy, valid instruments) may be violated despite sensitivity tests
- Clinical translation requires prospective trials; effect sizes for overall OC were borderline
Future Directions: Design ENOC-enriched trials of GLP-1R agonists with metabolic biomarker panels; validate mediation pathways and evaluate prevention potential.
BACKGROUND: Ovarian cancer is a major female reproductive health issue with heterogeneous biological features on its subtypes, which may require different therapeutic strategies. Glucagon-like peptide-1 receptor (GLP-1R) agonists were reported to be beneficial for ovarian cancer, but the causal effects and mechanisms on its heterogeneous subtypes remain unclear. METHODS: We used genetic variants robustly associated with gene expression, protein level, splicing event, and DNA methylation of GLP-1R in six endocrine-related tissues (N ≤ 35,431) as genetic instruments to proxy the effect of GLP-1R agonism. To increase power, we conducted a meta-analysis of genome-wide association studies of ovarian cancer (29,066 cases, 461,542 controls), and identified 12 genome-wide associated variants, including two previously unreported variants: rs77247401 (MIR1208) and rs56159231 (PLEKHM1). RESULTS: Here we show that gene expression of GLP-1R in pancreas is associated with a reduced risk of overall ovarian cancer risk odds ratio ([OR] = 0.94, 95% confidence interval [CI] 0.89-1.00) and endometrioid ovarian cancer (ENOC; OR = 0.83, 95% CI = 0.72-0.95), which the finding is validated using splicing event of GLP-1R in pancreas (OR = 0.13, 95% CI = 0.02-0.86). However, null association is found for GLP-1R expression in pancreas with other ovarian cancer subtypes. The phenome-wide MR followed by mediation MR identifies six body composition and metabolic factors as mediators, including 18:2 linoleic acid. CONCLUSIONS: The protective effect of GLP-1R agonists on ovarian cancer, especially ENOC, needs further validation in large-scale and well-conducted clinical trials. The class of drugs known as GLP-1 receptor (GLP-1R) agonists are known to have a range of health benefits. However, their effect on ovarian cancer, which is a significant health concern for women worldwide, has been unclear. GLP-1R agonists act on a protein expressed in the outside of cells, called the GLP-1 receptor. In our study, we used human genetic data to predict activity of the GLP-1 receptor in over 490,000 individuals. We found that GLP-1R activity in the pancreas was associated with a lower risk of a specific subtype of ovarian cancer called endometrioid ovarian cancer. This protective effect appeared to be partly influenced by changes in body composition and molecules in the blood, such as linoleic acid. Our results suggest that GLP-1R agonists could help prevent certain forms of ovarian cancer. Further clinical studies are needed to confirm this possibility.
3. Comparative prognostic value of nine cardiorenal biomarkers for mortality among adults with prediabetes and diabetes.
In 4,087 adults with prediabetes/diabetes followed for a median of 16.5 years, NT-proBNP and hs-cTnT showed the strongest associations and discrimination for all-cause and cardio-cerebrovascular mortality, with cystatin C also ranking highly. Adding NT-proBNP or hs-cTnT significantly improved predictive performance.
Impact: Defines a pragmatic biomarker hierarchy for mortality risk in dysglycemia and demonstrates incremental value beyond traditional factors using national data.
Clinical Implications: Incorporating NT-proBNP and hs-cTnT into risk models for patients with prediabetes or diabetes may enhance identification of high-risk individuals and guide cardioprotective strategies.
Key Findings
- NT-proBNP and hs-cTnT had the strongest associations with all-cause mortality (HRs ~2.2–2.3) and high 10-year discrimination (AUC ~0.80–0.81).
- Cystatin C, β2-microglobulin, and UACR were also independently associated with mortality.
- Adding NT-proBNP or hs-cTnT improved prediction for all-cause and CCD mortality; WQS pointed to NT-proBNP, hs-cTnT, and cystatin C as dominant contributors.
Methodological Strengths
- Nationally representative cohort with long follow-up and adjudicated mortality linkage
- Survey-weighted Cox models, time-dependent ROC, and WQS regression for comprehensive evaluation
Limitations
- Observational design susceptible to residual confounding
- Single baseline biomarker measurements; potential regression dilution
Future Directions: Prospective validation of biomarker-enriched risk scores and evaluation of biomarker-guided interventions to reduce mortality in dysglycemia.
BACKGROUND: Cardiorenal biomarkers are increasingly recognized as valuable tools for risk stratification in individuals with dysglycemia. However, their comparative prognostic value for long-term all-cause and cardio-cerebrovascular disease (CCD) mortality remains unclear. METHODS: We analyzed data from 4087 adults with prediabetes or diabetes from NHANES 1999-2004, with mortality follow-up through 2019. Nine biomarkers were assessed: NT-proBNP, hs-cTnT, hs-cTnI, CRP, UACR, BUN/Cr ratio, uric acid, cystatin C, and β2-microglobulin. Survey-weighted Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for all-cause and CCD mortality. Time-dependent receiver operating characteristic (ROC) analysis evaluated discriminative performance. Weighted quantile sum (WQS) regression was applied to assess the collective impact of biomarkers. RESULTS: During a median follow-up of 16.5 years, 1855 all-cause deaths and 630 CCD deaths were recorded. In fully adjusted models, NT-proBNP (HR = 2.19; 95% CI, 1.73-2.78), hs-cTnT (HR = 2.30; 1.63-3.24), hs-cTnI (HR = 1.80; 1.44-2.24), cystatin C (HR = 1.76; 1.36-2.28), β2-microglobulin (HR = 1.72; 1.36-2.16), and UACR (HR = 1.50; 1.23-1.81) were significantly associated with all-cause mortality, with similar findings for CCD mortality. NT-proBNP and hs-cTnT demonstrated the strongest discrimination for 10-year all-cause (AUCs: 0.80 and 0.81) and CCD mortality (AUCs: both 0.85). Adding NT-proBNP or hs-cTnT to the base model significantly improved predictive accuracy. WQS regression confirmed a significant positive association with all-cause (HR = 1.56; 95% CI, 1.32-1.84) and CCD mortality (HR = 1.39; 95% CI, 1.14-1.70), with NT-proBNP, hs-cTnT, and cystatin C contributing most strongly. CONCLUSIONS: Among nine evaluated cardiorenal biomarkers, NT-proBNP, hs-cTnT, and cystatin C demonstrated the strongest and most consistent associations with all-cause and CCD mortality among adults with prediabetes and diabetes, as well as the highest incremental predictive value. These biomarkers may serve as key components in future risk stratification models for individuals with prediabetes or diabetes.